2023
Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: An ILROG Multi-Institutional Study
Yegya-Raman N, Wright C, Ladbury C, Chew J, Zhang S, Sun S, Burke S, Baron J, Sim A, LaRiviere M, Yang J, Robinson T, Tseng Y, Terezakis S, Braunstein S, Dandapani S, Schuster S, Chong E, Plastaras J, Figura N. Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: An ILROG Multi-Institutional Study. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s50-s51. DOI: 10.1016/j.ijrobp.2023.06.333.Peer-Reviewed Original ResearchImmune effector cell-associated neurotoxicity syndromeProgression-free survivalCytokine release syndromeB-cell lymphomaChimeric antigen receptor T-cell therapySuperior progression-free survivalLarge B-cell lymphomaCAR-T infusionT-cell therapyMulti-institutional studyOverall survivalCTCAE v5.0T infusionTisa-celCAR TRefractory aggressive B-cell lymphomasStage III/IV diseaseT-cell/histiocyte-rich large B-cell lymphomaFavorable progression-free survivalCentral nervous system involvementDiffuse large B-cell lymphomaAggressive B-cell lymphomasPrimary mediastinal B-cell lymphomaMediastinal B-cell lymphomaNervous system involvement
2021
In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas
Sim A, Figura N, Dohm A, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu H, Kim S, Locke F, Jain M, Robinson T. In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s131. DOI: 10.1016/j.ijrobp.2021.07.297.Peer-Reviewed Original ResearchMetabolic tumor volumeRefractory large B-cell lymphomaCAR T-cell infusionLarge B-cell lymphomaT-cell infusionT-cell therapyB-cell lymphomaTreatment failureChimeric antigen receptor T-cell therapyField local control rateCAR T-cell therapyBaseline PET/CTLocal failureCAR-T infusionExperience disease progressionLower RT dosesDisease-free survivalLocal control rateMajority of patientsAdequate local controlCAR-T therapyPatterns of failurePET/CTMATERIAL/METHODSCommon regimens
2018
Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel
Jain M, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Liu H, Falchook A, Robinson T, Kim S, Locke F. Radiation Therapy As a Bridging Strategy for Refractory Diffuse Large B Cell Lymphoma Patients Awaiting CAR T Manufacturing of Axicabtagene Ciloleucel. Blood 2018, 132: 4220. DOI: 10.1182/blood-2018-99-117133.Peer-Reviewed Original ResearchCytokine release syndromeAxi-cel therapyCAR-T infusionCy conditioningCase seriesT infusionTumor burdenAxicabtagene ciloleucelCAR TSpeakers bureauRadiation therapyRefractory diffuse large B-cell lymphoma patientsRefractory diffuse large B-cell lymphomaChimeric antigen receptor T-cell therapyPatient experienced progressive diseaseSevere cytokine release syndromeDiffuse large B-cell lymphoma patientsDisease controlLarge B-cell lymphoma patientsB-cell lymphoma patientsDiffuse large B-cell lymphomaAdvisory CommitteeLarge B-cell lymphomaCAR T cell efficacyExperienced progressive disease